Though CMC barriers remain, strategic planning in the early development stages can guide a CGT product to success, noted ...
FDA proposals include ‘major updates’ to simplify biosimilarity studies, reduce unnecessary clinical testing, and ease the process for making biosimilars interchangeable with brand-name biologics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback